Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 334 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate Psoriasis Clear all
Suspended Phase 2 Interventional

Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

NCT06723171
View directory record Official record
Conditions
Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
Interventions
IRX4204, Placebo
Drug · Other
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

NCT02969018
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
PF-06700841, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
30
States / cities
Rogers, Arkansas • Anaheim, California • Encinitas, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 30, 2026, 4:27 PM EDT
Terminated Phase 4 Interventional Results available

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

NCT01543204
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT06176768
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
LY3972406, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Santa Monica, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

NCT02425826
View directory record Official record
Conditions
Parapsoriasis
Interventions
Apremilast, Placebo, Placebo-Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

NCT01777191
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Anaheim, California • Bakersfield, California • Santa Monica, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Plaque Psoriasis Study in Pediatric Subjects

NCT02186665
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
calcitriol ointment, placebo comparator
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
2 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

NCT01714544
View directory record Official record
Conditions
Psoriasis
Interventions
Cloderm Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
Cincinnati, Ohio • Portland, Oregon • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

NCT06846541
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis
Interventions
Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
1,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Chandler, Arizona • Pheonix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

NCT01206660
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone Spray 0.25%, placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hazleton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 30, 2026, 4:27 PM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

NCT05344482
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

NCT05600036
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ESK-001, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

NCT00885196
View directory record Official record
Conditions
Moderate and Severe Plaque Psoriasis
Interventions
Placebo, AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
10
States / cities
Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

NCT01384630
View directory record Official record
Conditions
Psoriasis
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Owensboro, Kentucky • Ann Arbor, Michigan • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

NCT00147329
View directory record Official record
Conditions
Psoriasis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2007 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475
View directory record Official record
Conditions
Psoriasis
Interventions
Risankizumab, Apremilast
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis

NCT01090063
View directory record Official record
Conditions
Moderate to Severe Palmar Plantar Psoriasis
Interventions
Ustekinumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326298
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 30, 2026, 4:27 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s

NCT03079973
View directory record Official record
Conditions
Nail Psoriasis
Interventions
P-3073 (calcipotriene 0.005%), Vehicle of P-3073
Drug
Lead sponsor
Polichem S.A.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 30, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

NCT04718896
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cypress, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 4:27 PM EDT
Active, not recruiting Phase 2 Interventional

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 4:27 PM EDT